Compare SoundHound AI Inc (SOUN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs State Street SPDR S&P Biotech ETF — how do they compare? SoundHound AI Inc trades at $6.56 (market cap $2.75B), while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| SOUN | XBI | |
|---|---|---|
Market Cap | $2.75B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $21.40 | $164.28 |
52-Week Low | $5.90 | $85.16 |
Enterprise Value | $2.54B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $6.31, up 0.64% today, but remains down 37% year-to-date. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $168.92 million in 2025, but net losses widened to -$14.01 million. Recent news highlights its leadership in conversational AI, yet concerns over cash burn persist. Analyst consensus is bullish with a $13.00 price target, indicating significant potential upside from current levels.
Outlook: High growth potential in voice AI markets contrasts with persistent losses and negative cash flow. Investment opportunity lies in market expansion and acquisitions, but risks include execution challenges and sustained cash burn. Investors should weigh the bullish analyst targets against the company's current unprofitability and high valuation multiples.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
